Bioatla announces closing of initial public offering and full exercise of the underwriters' option to purchase additional shares

San diego, dec. 18, 2020 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial...
BCAB Ratings Summary
BCAB Quant Ranking